Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
ABIVAX announces positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464

ABX464 is a first-in-class orally available antiviral drug candidate for the treatment of patients with HIV infection. It blocks HIV replication through a unique mechanism of action that leads to the destruction of viral RNA. A dose-dependent increase in the response rate to ABX464 monotherapy was observed in the study. The majority of patients who received the highest dose (150 mg) showed a viral load reduction of at least 0.5 log (greater than 68% reduction) during the treatment period.

Published
13 January 2016
From
Medical News Today
New amfAR/UCSF Institute Aims to Advance Basic Science of HIV Cure Research

The new institute will focus on 4 key areas: learning how latent viral reservoir are formed and persist in the body, determining the precise locations of these reservoirs, quantifying the amount of virus in them, and eradicating the reservoirs from the body.

Published
13 January 2016
From
HIVandhepatitis.com
Short- or Medium-Term PrEP Is Safer Than Aspirin

Truvada as pre-exposure prophylaxis (PrEP) against HIV has comparable safety to aspirin, at least for the short- and medium-term.

Published
13 January 2016
From
AIDSMeds
Janssen, ViiV Healthcare Formalize Injectable Rilpivirine + Cabotegravir Phase 3 as HIV Treatment

Janssen Sciences Ireland UC (Janssen), formalized its collaboration with ViiV Healthcare on phase III development and commercialization of a two drug regimen of two long acting, all-injectable formulations of rilpivirine (a non-nucleoside reverse transcriptase inhibitor by Janssen) and cabotegravir (ViiV Healthcare).

Published
08 January 2016
From
Street Insider
Undetectable & Low-level HIV Viral Replication

Even people who are adherent to their medication regimens may experience occasional “blips” in their viral loads, experience viral rebound or maintain a steady, if low, viral load above undetectable levels. To understand why some people struggle to achieve or remain undetectable, we spoke with Keith Henry, MD, an HIV specialist at Hennepin County Medical Center who has more than 25 years of experience caring for people with HIV.

Published
06 January 2016
From
BETA blog
Young Men With Detectable Viral Loads More Likely to Engage in Risky Behavior

A new study on HIV-positive men and transgender women who have sex with men reported that participants with detectable viral loads were more likely to have anal sex without condoms than those who were virally suppressed, and that condom use was closely related to substance abuse. The study examined participants age 15 to 26 across the US from 2009 to 2012. Among those who had detectable viral loads, a full 44 percent reported condomless sex, a significant percentage higher than those who were virally suppressed but had condomless sex (which was only 25 percent).

Published
05 January 2016
From
HIVPlusMag
HIV salvage regimens can safely omit NRTIs, says US study

Nucleoside reverse transcriptase inhibitors (NRTIs) can be safely omitted from HIV salvage therapy, investigators from the United States report in the Annals of Internal Medicine. The findings

Published
04 January 2016
By
Michael Carter
$4.2M Grant to 'Kick and Kill' Latent HIV Using New Class of Meds

Tulane researchers will also test a gene editing strategy that delivers therapy tailored to each individual’s immune system.

Published
29 December 2015
From
Poz magazine news
HIV Antibody Infusion Safely Suppresses Virus in Infected People

A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in a paper published today.

Published
24 December 2015
From
National Institute of Allergy and Infectious Diseases (NIAID)
Many patients on new HCV medications at risk of drug-drug interactions

Many patients taking direct acting antivirals (DAA) to treat hepatitis C virus (HCV) are at risk of clinically significant drug-drug interactions (DDIs), new research shows.

Published
23 December 2015
From
Medscape (requires free registration)

Filter by country